Reduction of testosterone synthesis after high dose interleukin-2 therapy of metastatic cancer.

Meikle, A W; Cardoso de Sousa, J C; Ward, J H; Woodward, M; Samlowski, W E

Meikle, A W; Cardoso de Sousa, J C; Ward, J H; Woodward, M; Samlowski, W E.

Affiliation

Meikle AW; Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City 84132.

J Clin Endocrinol Metab ; 73(5): 931-5, 1991 Nov.

Article in En | MEDLINE | ID: mdl-1834690

Subject(s)

Carcinoma, Renal Cell/therapy; Interleukin-2/therapeutic use; Kidney Neoplasms/therapy; Melanoma/therapy; Testosterone/blood; Adult; Carcinoma, Renal Cell/blood; Dehydroepiandrosterone/analogs & derivatives; Dehydroepiandrosterone/blood; Dehydroepiandrosterone Sulfate; Estradiol/blood; Follicle Stimulating Hormone/blood; Humans; Hydrocortisone/blood; Kidney Neoplasms/blood; Male; Melanoma/blood; Middle Aged; Neoplasm Metastasis; Recombinant Proteins/therapeutic use; Testosterone/biosynthesis; Time Factors

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Main subject: Testosterone / Carcinoma, Renal Cell / Interleukin-2 / Kidney Neoplasms / Melanoma Language: En Journal: J Clin Endocrinol Metab Year: 1991 Type: Article

Search on Google

Add to My VHL

XML

PubMed Links